Oritavancin - Glycopeptide Antibiotic for Multidrug-Resistant Gram-Positive Pathogens
Key Data:
Drug (brand/generic)
Oritavancin
Company/Licensee
Targanta Therapeutics
Therapy Class
Glycopeptide
Product Description
Antibiotic
Current Indication
Treatment of complicated skin and soft tissue infections due to gram-positive pathogens
Market Sector
Anti-infectives
Development Status
Pre-registration
